Status:
COMPLETED
Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.
Eligibility Criteria
Inclusion
- Infected with hepatitis C virus
Exclusion
- Contraindications to peginterferon or ribavirin therapy.
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00262483
Start Date
December 1 2005
End Date
April 1 2006
Last Update
December 21 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Call for information
San Antonio, Texas, United States
2
Call for information
Santurce, Puerto Rico